2025台湾地区血胆固醇管理临床路径共识。

IF 1.8 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Yi-Heng Li, Chung-Liang Shih
{"title":"2025台湾地区血胆固醇管理临床路径共识。","authors":"Yi-Heng Li, Chung-Liang Shih","doi":"10.6515/ACS.202503_41(2).20250215A","DOIUrl":null,"url":null,"abstract":"<p><p>Increased low-density lipoprotein cholesterol (LDL-C) is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD). However, the attainment rate of recommended LDL-C targets is not optimal with significant scope for improvement in Taiwan. This clinical pathway for cholesterol management was developed based on the Taiwan lipid guidelines and expert opinions from major medical societies in Taiwan. It was designed with the aim of improving the outcomes of people at risk of or with ASCVD who would benefit from lipid control to reduce the risk of new or recurrent cardiac events. The pathway proposes adequate LDL-C targets for people at different risk levels of ASCVD and standardizes lipid management and follow-up in patients receiving lipid lowering therapy. The ultimate purpose is to facilitate the attainment of individual LDL-C targets and ensure that patients are monitored adequately and optimized on the appropriate lipid lowering therapy to reduce the risk of ASCVD.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"41 2","pages":"161-165"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923786/pdf/","citationCount":"0","resultStr":"{\"title\":\"2025 Consensus on the Clinical Pathway of Blood Cholesterol Management in Taiwan.\",\"authors\":\"Yi-Heng Li, Chung-Liang Shih\",\"doi\":\"10.6515/ACS.202503_41(2).20250215A\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Increased low-density lipoprotein cholesterol (LDL-C) is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD). However, the attainment rate of recommended LDL-C targets is not optimal with significant scope for improvement in Taiwan. This clinical pathway for cholesterol management was developed based on the Taiwan lipid guidelines and expert opinions from major medical societies in Taiwan. It was designed with the aim of improving the outcomes of people at risk of or with ASCVD who would benefit from lipid control to reduce the risk of new or recurrent cardiac events. The pathway proposes adequate LDL-C targets for people at different risk levels of ASCVD and standardizes lipid management and follow-up in patients receiving lipid lowering therapy. The ultimate purpose is to facilitate the attainment of individual LDL-C targets and ensure that patients are monitored adequately and optimized on the appropriate lipid lowering therapy to reduce the risk of ASCVD.</p>\",\"PeriodicalId\":6957,\"journal\":{\"name\":\"Acta Cardiologica Sinica\",\"volume\":\"41 2\",\"pages\":\"161-165\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923786/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Cardiologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6515/ACS.202503_41(2).20250215A\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202503_41(2).20250215A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

低密度脂蛋白胆固醇(LDL-C)升高是动脉粥样硬化性心血管疾病(ASCVD)最重要的危险因素之一。然而,台湾地区低密度脂蛋白建议指标的达标率并不理想,仍有显著的改善空间。本胆固醇管理的临床路径是根据台湾血脂指南和台湾主要医学学会的专家意见而制定的。它的设计目的是改善ASCVD风险或ASCVD患者的预后,这些患者将受益于脂质控制,以降低新发或复发心脏事件的风险。该途径为不同风险水平的ASCVD患者提供了适当的LDL-C靶点,并规范了接受降脂治疗的患者的脂质管理和随访。最终目的是促进个体LDL-C目标的实现,确保对患者进行充分监测并优化适当的降脂治疗,以降低ASCVD的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
2025 Consensus on the Clinical Pathway of Blood Cholesterol Management in Taiwan.

Increased low-density lipoprotein cholesterol (LDL-C) is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD). However, the attainment rate of recommended LDL-C targets is not optimal with significant scope for improvement in Taiwan. This clinical pathway for cholesterol management was developed based on the Taiwan lipid guidelines and expert opinions from major medical societies in Taiwan. It was designed with the aim of improving the outcomes of people at risk of or with ASCVD who would benefit from lipid control to reduce the risk of new or recurrent cardiac events. The pathway proposes adequate LDL-C targets for people at different risk levels of ASCVD and standardizes lipid management and follow-up in patients receiving lipid lowering therapy. The ultimate purpose is to facilitate the attainment of individual LDL-C targets and ensure that patients are monitored adequately and optimized on the appropriate lipid lowering therapy to reduce the risk of ASCVD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Cardiologica Sinica
Acta Cardiologica Sinica 医学-心血管系统
CiteScore
2.90
自引率
15.80%
发文量
144
审稿时长
>12 weeks
期刊介绍: Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信